Report scope. This 2026 Drug Asset Due Diligence Report evaluates Genistein as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Genistein is a Small molecule drug associated with SRC x Top II and a global highest development stage of Phase 2. The lead disclosed indication is Interstitial lung disease due to connective tissue disease. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Genistein
- Target: SRC x Top II
- Lead indication: Interstitial lung disease due to connective tissue disease
- Highest phase: Phase 2
- Matched trials: 6
- Matched result records: 14
- Matched asset deals: 1
Use PatSnap Life Sciences MCP servers to validate the Genistein diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Genistein, the MCP profile identifies SRC x Top II as the primary target context and Interstitial lung disease due to connective tissue disease as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Genistein diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07323732 | Phase 2 | Recruiting | Not disclosed | Not disclosed |
| NCT07033767 | Phase 1/2 | Not yet recruiting | Not disclosed | Not disclosed |
| CTRI/2025/03/083415 | Phase 2 | Not Yet Recruiting | Not disclosed | Not disclosed |
| NCT06741345 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT06634108 | Phase 1/2 | Recruiting | Not disclosed | Not disclosed |
| NCT06501768 | Phase 1/2 | Unknown status | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Genistein diligence evidence.
3. Clinical readouts: what is known
Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy
Study: NCT01489813 (CTgov). Phase: Phase 2. Enrollment: 36. Published: 2024-07-25.
Change in Severity of Urinary Symptoms as Determined by the The International Prostate Symptom Score (IPSS) Questionnaire Score.(Median) = -2 Point (Full Range, -3 to 2) | Change in Severity of Urinary Symptoms as Determined by the The International Prostate Symptom Score (IPSS) Questionnaire Score.(Median) = -3 Point (Full Range, -4 to 2)
A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy
Study: NCT02624388 (UVA-Gen001, CTgov). Phase: Phase 2. Enrollment: 4. Published: 2024-05-06.
Genistein cycles(Mean) = 13.75 Day | Genistein cycles(Mean) = 12.67 Day
A Phase 1 Dose Escalation Trial Evaluating the Safety and Pharmacokinetic Profile of BIO 300 Oral Powder in Healthy Volunteers
Study: NCT04650555 (CTgov). Phase: Phase 1. Enrollment: 34. Published: 2024-05-03.
Screening(Mean) = 407 ms | DLT = 0 Number of Adverse Events
A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
Study: NCT02567799 (NSCLC, CTgov). Phase: Phase 1/2. Enrollment: 21. Published: 2023-12-20.
Number of Participants With Adverse Events Throughout the Study = 7 Pts | Number of Participants With Adverse Events Throughout the Study = 7 Pts
Humanetics Corporation Publishes Positive Clinical Trial Results of BIO 300 in Patients with Non-Small Cell Lung Cancer
Study: NCT02567799 (Biospace). Phase: Phase 1/2. Enrollment: 21. Published: 2023-09-19.
DLT = 0 %
Safety, Pharmacokinetics, and Biomarkers of an Amorphous Solid Dispersion of Genistein, a Radioprotectant, in Healthy Volunteers
Study: NCT04650555 (Pubmed | Clin Pharmacol Drug Dev). Phase: Phase 1. Enrollment: 34. Published: 2022-10-27.
AE = mild to moderate gastrointestinal events, and no dose-limiting toxicities were reported.
Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer
Study: NCT02766478 (GeniPro, CTgov). Phase: Phase 2. Enrollment: 10. Published: 2022-09-27.
Baseline(Median) = 4.4 index (IQR, 2.4 - 5.5) | Baseline(Median) = 6.1 index (IQR, 3.9 - 13.5)
Humanetics Corporation Announces Results from Phase 1 Trial of BIO 300 Oral Powder
Study: NCT04650555 (BusinessWire). Phase: Phase 1. Enrollment: 34. Published: 2021-09-22.
Survival = increase survival in persons exposed to lethal levels of radiation
Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study
Study: NCT01985763 (Pubmed | Cancer Chemother Pharmacol). Phase: Phase 1/2. Enrollment: 13. Published: 2019-09-01.
AE = 1patirent (grade 3 hypertension)
Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study
Study: NCT01985763 (CTgov). Phase: Phase 1/2. Enrollment: 13. Published: 2019-05-10.
Grade 1 = 250 Event
Phase IIB Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer
Study: NCT00290758 (CTgov). Phase: Phase 2. Enrollment: 126. Published: 2017-02-08.
Postmenopausal with ER- Cancer(Mean) = 2251.92 pg/mL | Postmenopausal with ER+ Cancer(Mean) = -497.3 pg/mL
Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy
Study: NCT01325311 (CTgov). Phase: Phase 2. Enrollment: 15. Published: 2016-08-03.
Tissue Levels of Calcitriol Between the Placebo and Cholecalciferol/Genistein Arms(Mean) = 0.045 ng/mL | Tissue Levels of Calcitriol Between the Placebo and Cholecalciferol/Genistein Arms(Mean) = 0.057 ng/mL
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
Study: NCT00118040 (CTgov). Phase: Phase 2. Enrollment: 60. Published: 2016-03-24.
Strong = 93.33 percentage of pEGFR strength signal | Other (Not Including Serious) Adverse Events = 18 Pts
732 GENISTEIN INHIBITS PROSTATE CANCER METASTASIS BY PREVENTING CELL DETACHMENT
Study: 732 (AUA2011). Phase: Phase 2. Enrollment: Not disclosed. Published: 2011-04-01.
Area = 2.0 % (95%CI, +/ - 1.0)
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Genistein diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Genistein against approved therapies and clinical competitors in Interstitial lung disease due to connective tissue disease, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Genistein diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2018-01-30 | StemoniX collaborates with Humanetics to study the effectiveness of BIO-300 in treating radiation-induced cardiovascular disease. | Active | Collaboration | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Genistein diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
